Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
出版年份 2023 全文链接
标题
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
作者
关键词
-
出版物
LANCET
Volume 402, Issue 10405, Pages 859-870
出版商
Elsevier BV
发表日期
2023-08-15
DOI
10.1016/s0140-6736(23)01554-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-Term Outcomes in IgA Nephropathy
- (2023) David Pitcher et al. Clinical Journal of the American Society of Nephrology
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
- (2022) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
- (2022) Jonathan Barratt et al. KIDNEY INTERNATIONAL
- One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy
- (2022) Richard A. Lafayette et al. Kidney International Reports
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
- (2021) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Why Target the Gut to Treat IgA Nephropathy?
- (2020) Jonathan Barratt et al. Kidney International Reports
- GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
- (2019) Lesley A. Inker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- The Gut-Renal Connection in IgA Nephropathy
- (2018) Rosanna Coppo SEMINARS IN NEPHROLOGY
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
- (2017) Bengt C Fellström et al. LANCET
- IgA nephropathy
- (2016) Kar Neng Lai et al. Nature Reviews Disease Primers
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The genetics and immunobiology of IgA nephropathy
- (2014) Krzysztof Kiryluk et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognosis in IgA Nephropathy: 30-Year Analysis of 1,012 Patients at a Single Center in Japan
- (2014) Takahito Moriyama et al. PLoS One
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- An update on the pathogenesis and treatment of IgA nephropathy
- (2012) Joanna K. Boyd et al. KIDNEY INTERNATIONAL
- Mice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy
- (2011) Douglas D. McCarthy et al. JOURNAL OF CLINICAL INVESTIGATION
- New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria
- (2011) H. K. Smerud et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search